newsfilter
← Latest News
Business Wire·

Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease

GPH101 is an investigational next-generation gene-edited therapy designed to potentially provide a one-time cure for patients Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-effici